Needham analyst Joseph Stringer maintained a Buy rating on BioAge Labs, Inc. today and set a price target of $50.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Joseph Stringer has given his Buy rating due to a combination of factors related to BioAge Labs, Inc.’s lead asset BGE-102. He points to newly reported Phase 1 multiple-ascending-dose data in obese subjects with high baseline inflammation, where once-daily 60 mg dosing produced substantial median declines in hsCRP and brought the majority of patients down to normal inflammatory ranges.
He views these results as a strong confirmation of earlier Phase 1 readouts disclosed in late 2025 and updated in early 2026, reinforcing confidence in BGE-102’s profile as a potential best-in-class oral NLRP3 inhibitor. Stringer also highlights that the clean and efficacious dataset paves the way for a mid-2026 Phase 2 cardiovascular risk trial, with year-end 2026 data expected, which in his view creates a clear value-creation pathway that supports a Buy recommendation on BIOA.
According to TipRanks, Stringer is a 5-star analyst with an average return of 25.4% and a 48.58% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Rhythm Pharmaceuticals, and Stoke Therapeutics.